Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lenard Lichtenberger
University of Texas Hlth Sci Ctr Houston, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
PLx Pharma Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lichtenberger holds equity in PLx Pharma Inc. and serves as a paid consultant. The company was formed to commercialize novel formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs) that are safer for the gastrointestinal tract. The institution licenses intellectual property to PLx Pharma Inc. and Dr. Lichtenberger participates in research that is related to the licensed technology.
Effects of Antiplatelet Drugs on Colon Cancer in the Elderly
Colorectal cancer is the second leading cause of cancer-related deaths in the U.S. and its incidence increases with age. There is sufficient scientific and clinical information available to support the use of antiplatelet drugs such as low-dose aspirin as chemopreventive agents in patients at risk for this disease, but the side effect of aspirin to caus bleeding and ulceration of the gastrointestinal (GI) tract, as well as unknown age-related effectiveness of some drugs, limit the recommendation for use of these agents. The drugs under study in this proposal include a new formulation of aspirin that is safer for the GI tract (aspirin PC) and other antiplatelet drugs that are readily available and may enhance the chemopreventive action of aspirin. These studies have the potential to save lives and healthcare dollars by testing relatively low cost drugs that can prevent a fatal disease (colorectal cancer) and also avoid life-threatening side effects (bleeding).
Filed on May 27, 2014.
Tell us what you know about Lenard Lichtenberger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Lenard Lichtenberger filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lenard Lichtenberger | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | PLx Pharma Inc. | $40,000 - $59,999 |
| Lenard Lichtenberger | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | PLx Pharma, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.